The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder. Approval of ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...